These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 27229707

  • 1. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion.
    Moon J, Kim M, Sagong M.
    Eye (Lond); 2016 Aug; 30(8):1084-90. PubMed ID: 27229707
    [Abstract] [Full Text] [Related]

  • 2. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X, Li J, Hu X, Yu S, Pan J, Tang S.
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [Abstract] [Full Text] [Related]

  • 3. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
    Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
    [Abstract] [Full Text] [Related]

  • 4. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions.
    Tomomatsu Y, Tomomatsu T, Takamura Y, Gozawa M, Arimura S, Takihara Y, Inatani M.
    Acta Ophthalmol; 2016 May; 94(3):e225-30. PubMed ID: 25989706
    [Abstract] [Full Text] [Related]

  • 5. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
    Liu Q, Hu Y, Yu H, Yuan L, Hu J, Atik A, Guan M, Li D, Li X, Tang S.
    Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.
    Moon SY, Cho KH, Woo SJ, Park SP, Kim YK.
    Korean J Ophthalmol; 2018 Feb; 32(1):29-37. PubMed ID: 29376223
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion.
    Kwon SI, Kim YW, Bang YW, Lee JY, Park IW.
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):5-9. PubMed ID: 23237542
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.
    Zhao L, Li B, Feng K, Han L, Ma Z, Liu Y.
    Curr Eye Res; 2015 Jul; 40(7):752-6. PubMed ID: 25330134
    [Abstract] [Full Text] [Related]

  • 12. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.
    Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C.
    Eur J Ophthalmol; 2012 Jul; 22(4):607-14. PubMed ID: 22101497
    [Abstract] [Full Text] [Related]

  • 13. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
    Bakri SJ, Larson TA.
    Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Tsagkataki M, Papathomas T, Lythgoe D, Kamal A.
    Semin Ophthalmol; 2015 Jul; 30(5-6):352-9. PubMed ID: 24875368
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections.
    Alshareef RA, Garg SJ, Hsu J, Vander J, Park C, Spirn MJ.
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):512-6. PubMed ID: 24828198
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.